Cancer and Careers

Once you’ve beaten cancer, you jut go back to work and everything is fine, right? Not necessarily. Most people say they are anxious about how their work life will play out. In a survey of 29 cancer survivors, researchers found that:

• One-third found it difficult to cope and concentrate initially and worried about their productivity once they got back to work.

• The more stressful the job, the more difficult the re-entry.

• The larger the company, in general, the easier the transition because accommodations were often more plentiful.

A new organization, Cancer and Careers, provides a free workbook, educational resources, support and information for both cancer patients and survivors, as well as coworkers, managers, CEOs and human resources personnel about cancer patients and survivors working through their treatment and returning to work.

They offer forms, checklists, inspiring stories and plenty of helpful advice. For example, if your gap in employment due to your cancer treatment is greater than a year, write a "functional" resume--one that is skills-based, not chronologically-based.

For more information, go to: www.cancerandcareers.org

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap